Theodore W. Laetsch, MD; Jaclyn F. Hechtman, MD; Frédérique Penault-Llorca, MD, PhD
The goal of this activity is to increase awareness of rare targetable genetic alterations and affirm best practices for sampling, testing, and reporting results of molecular characterization of solid tumors.
This activity is intended for pathologists and oncologists.
Upon completion of this activity, participants will:
- Have increased knowledge regarding the
- Merits of diagnostic techniques in determining whether a tumor harbors a rare mutation
- Have greater competence related to
- Selecting the most appropriate testing strategy for detection of oncogenic driver mutations to allow accurate characterization of a patient's cancer
- Accurate reporting of biomarker test results to other members of the care team to help guide optimal treatment selection
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.